OJTS  Vol.3 No.4 , December 2013
Inflammation Biomarkers as Predictors of Pulmonary Outcomes in Cardiac Surgical Patients
Prolonged ventilator support, pulmonary infections and the need for tracheostomies after cardiac operations are associated with increased hospital mortality, length of stay, cost of hospitalization and reduced long term survival. The objective of this study is to review the literature and develop and present an understanding of the potential role of specific pre-operatively or intraoperatively collected inflammatory biomarkers and their role as predictors of pulmonary outcomes in cardiac surgery.

Cite this paper
N. Sweiss, R. Sawaqed, K. Leeper, H. Kelli, T. Niewold and O. Lattouf, "Inflammation Biomarkers as Predictors of Pulmonary Outcomes in Cardiac Surgical Patients," Open Journal of Thoracic Surgery, Vol. 3 No. 4, 2013, pp. 93-102. doi: 10.4236/ojts.2013.34020.
[1]   D. Lloyd-Jones, R. J. Adams, T. M. Brown, M. Carnethon, S. Dai, et al., “Heart Disease and Stroke Statistics—2010 Update: A Report from the American Heart Association,” Circulation, Vol. 121, 2010, pp. e46-e215. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192667

[2]   K. A. Eagle, R. A. Guyton, R. Davidoff, F. H. Edwards, G. A. Ewy, et al., “ACC/AHA 2004 Guideline Update for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery),” Circulation, Vol. 110, No. 14, 2004, pp. e340-e437. http://dx.doi.org/10.1161/01.CIR.0000138790.14877.7D

[3]   T. B. Ferguson Jr., B. G. Hammill, E. D. Peterson, E. R. DeLong and F. L. Grover, “A Decade of Change—Risk Profiles and Outcomes for Isolated Coronary Artery Bypass Grafting Procedures, 1990-1999: A Report from the STS National Database Committee and the Duke Clinical Research Institute. Society of Thoracic Surgeons,” The Annals of Thoracic Surgery, Vol. 73, No. 2, 2002, pp. 480-489. http://dx.doi.org/10.1016/S0003-4975(01)03339-2

[4]   P. K. Henke, “Improving Quality of Care in Vascular Surgery: The Tools Are Available Now,” The American Journal of Surgery, Vol. 190, No. 2, 2005, pp. 333-337. http://dx.doi.org/10.1016/j.amjsurg.2005.05.036

[5]   E. H. Hulzebos, P. J. Helders, N. J. Favie, R. A. De Bie, A. B. de la Riviere, et al., “Preoperative Intensive Inspiratory Muscle Training to Prevent Postoperative Pulmonary Complications in High-Risk Patients Undergoing CABG Surgery: A Randomized Clinical Trial,” JAMA, Vol. 296, No. 15, 2006, pp. 1851-1857. http://dx.doi.org/10.1001/jama.296.15.1851

[6]   L. Jensen and L. Yang, “Risk Factors for Postoperative Pulmonary Complications in Coronary Artery Bypass Graft Surgery Patients,” European Journal of Cardiovascular Nursing, Vol. 6, No. 3, 2007, pp. 241-246. http://dx.doi.org/10.1016/j.ejcnurse.2006.11.001

[7]   S. C. Murthy, A. C. Arroliga, P. A. Walts, J. Feng, J. P. Yared, et al., “Ventilatory Dependency after Cardiovascular Surgery,” The Journal of Thoracic and Cardiovascular Surgery, Vol. 134, No. 2, 2007, pp. 484-490. http://dx.doi.org/10.1016/j.jtcvs.2007.03.006

[8]   I. Yanez-Brage, S. Pita-Fernandez, A. Juffe-Stein, U. Martinez-Gonzalez, S. Pertega-Diaz, et al., “Respiratory Physiotherapy and Incidence of Pulmonary Complications in Off-Pump Coronary Artery Bypass Graft Surgery: An Observational Follow-Up Study,” BMC Pulmonary Medicine, Vol. 9, 2009, p. 36. http://dx.doi.org/10.1186/1471-2466-9-36

[9]   J. F. Legare, G. M. Hirsch, K. J. Buth, C. MacDougall and J. A. Sullivan, “Preoperative Prediction of Prolonged Mechanical Ventilation Following Coronary Artery Bypass Grafting,” European Journal Cardio-Thoracic Surgery, Vol. 20, No. 5, 2001, pp. 930-936. http://dx.doi.org/10.1016/S1010-7940(01)00940-X

[10]   T. D. Keenan, Y. Abu-Omar and D. P. Taggart, “Bypassing the Pump: Changing Practices in Coronary Artery Surgery,” Chest, Vol. 128, 2005, pp. 363-369. http://dx.doi.org/10.1378/chest.128.1.363

[11]   T. J. Ryan, “Present-Day PTCR versus CABG: A Randomized Comparison with a Different Focus and a New Result,” Journal of the American College of Cardiology, Vol. 37, No. 1, 2001, pp. 59-62. http://dx.doi.org/10.1016/S0735-1097(00)01051-2

[12]   A. L. Shroyer, F. L. Grover, B. Hattler, J. F. Collins, G. O. McDonald, et al., “On-Pump versus Off-Pump Coronary-Artery Bypass Surgery,” The New England Journal of Medicine, Vol. 361, No. 19, 2009, pp. 1827-1837. http://dx.doi.org/10.1056/NEJMoa0902905

[13]   M. Drakopoulou, K. Toutouzas, E. Stefanadi, E. Tsiamis, D. Tousoulis, et al., “Association of Inflammatory Markers with Angiographic Severity and Extent of Coronary Artery Disease,” Atherosclerosis, Vol. 206, No. 2, 2009, pp. 335-339. http://dx.doi.org/10.1016/j.atherosclerosis.2009.01.041

[14]   D. Tousoulis, M. Charakida and C. Stefanadis, “Endothelial Function and Inflammation in Coronary Artery Disease,” Postgraduate Medical Journal, Vol. 84, No. 993, 2008, pp. 368-371. http://dx.doi.org/10.1136/hrt.2005.066936

[15]   P. Libby, P. M. Ridker and G. K. Hansson, “Inflammation in Atherosclerosis: From Pathophysiology to Practice,” Journal of the American College of Cardiology, Vol. 54, No. 23, 2009, pp. 2129-2138. http://dx.doi.org/10.1016/j.jacc.2009.09.009

[16]   M. A. Gonzalez and A. P. Selwyn, “Endothelial Function, Inflammation, and Prognosis in Cardiovascular Disease,” American Journal of Medicine, Vol. 115, Suppl. 8A, 2003, pp. 99S-106S. http://dx.doi.org/10.1016/j.amjmed.2003.09.016

[17]   D. Behrendt and P. Ganz, “Endothelial Function. From Vascular Biology to Clinical Applications,” American Journal of Cardiology, Vol. 90, No. 10, 2002, pp. 40L-48L. http://dx.doi.org/10.1016/S0002-9149(02)02963-6

[18]   J. H. O’Keefe, M. D. Carter and C. J. Lavie, “Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach,” Mayo Clinic Proceedings, Vol. 84, No. 8, 2009, pp. 741-757. http://dx.doi.org/10.4065/84.8.741

[19]   V. Pasceri, J. T. Willerson and E. T. Yeh, “Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells,” Circulation, Vol. 102, No. 18, 2000, pp. 2165-2168. http://dx.doi.org/10.1161/01.CIR.102.18.2165

[20]   S. Fichtlscherer, G. Rosenberger, D. H. Walter, S. Breuer, S. Dimmeler, et al., “Elevated C-Reactive Protein Levels and Impaired Endothelial Vasoreactivity in Patients with Coronary Artery Disease,” Circulation, Vol. 102, No. 9, 2000, pp. 1000-1006. http://dx.doi.org/10.1161/01.CIR.102.9.1000

[21]   A. Tanaka, K. Shimada, T. Sano, M. Namba, T. Sakamoto, et al., “Multiple Plaque Rupture and C-Reactive Protein in Acute Myocardial Infarction,” Journal of the American College of Cardiology, Vol. 45, No. 10, 2005, pp. 1594-1599. http://dx.doi.org/10.1016/j.jacc.2005.01.053

[22]   I. Ikonomidis, C. A. Michalakeas, J. Lekakis, I. Paraskevaidis and D. T. Kremastinos, “Multimarker Approach in Cardiovascular Risk Prediction,” Disease Markers, Vol. 26, No. 5-6, 2009, pp. 273-285. http://dx.doi.org/10.1155/2009/135423

[23]   A. J. Grau, A. W. Boddy, D. A. Dukovic, F. Buggle, C. Lichy, et al., “Leukocyte Count as an Independent Predictor of Recurrent Ischemic Events,” Stroke, Vol. 35, No. 5, 2004, pp. 1147-1152. http://dx.doi.org/10.1161/01.STR.0000124122.71702.64

[24]   M. S. Elkind, R. R. Sciacca, B. Boden-Albala, T. Rundek, M. C. Paik, et al., “Relative Elevation in Baseline Leukocyte Count Predicts First Cerebral Infarction,” Neurology, Vol. 64, No. 12, 2005, pp. 2121-2125. http://dx.doi.org/10.1212/01.WNL.0000165989.12122.49

[25]   I. Ikonomidis, J. Lekakis, I. Revela, F. Andreotti and P. Nihoyannopoulos, “Increased Circulating C-Reactive Protein and Macrophage-Colony Stimulating Factor Are Complementary Predictors of Long-Term Outcome in Patients with Chronic Coronary Artery Disease,” European Heart Journal, Vol. 26, No. 16, 2005, pp. 1618-1624. http://dx.doi.org/10.1093/eurheartj/ehi192

[26]   I. Ikonomidis, F. Andreotti and P. Nihoyannopoulos, “Reduction of Daily Life Ischaemia by Aspirin in Patients with Angina: Underlying Link between Thromboxane A2 and Macrophage Colony Stimulating Factor,” Heart, Vol. 90, No. 4, 2004, pp. 389-393. http://dx.doi.org/10.1136/hrt.2003.015164

[27]   R. Bataille and B. Klein, “C-Reactive Protein Levels as a Direct Indicator of Interleukin-6 Levels in Humans in Vivo,” Arthritis & Rheumatism, Vol. 35, No. 8, 1992, pp. 982-984. http://dx.doi.org/10.1002/art.1780350824

[28]   M. Y. Abeywardena, W. R. Leifert, K. E. Warnes, J. N. Varghese and R. J. Head, “Cardiovascular Biology of Interleukin-6,” Current Pharmaceutical Design, Vol. 15, No. 15, 2009, pp. 1809-1821. http://dx.doi.org/10.2174/138161209788186290

[29]   N. Sarwar, A. J. Thompson and E. Di Angelantonio, “Markers of Inflammation and Risk of Coronary Heart Disease,” Disease Markers, Vol. 26, No. 5-6, 2009, pp. 217-225. http://dx.doi.org/10.1155/2009/851962

[30]   N. Nishimoto, “Interleukin-6 in Rheumatoid Arthritis,” Current Opinion in Rheumatology, Vol. 18, No. 3, 2006, pp. 277-281. http://dx.doi.org/10.1097/01.bor.0000218949.19860.d1

[31]   K. J. Warrington, P. D. Kent, R. L. Frye, J. F. Lymp, S. L. Kopecky, et al., “Rheumatoid Arthritis Is an Independent Risk Factor for Multi-Vessel Coronary Artery Disease: A Case Control Study,” Arthritis Research & Therapy, Vol. 7, No. 5, 2005, pp. R984-R991. http://dx.doi.org/10.1186/ar1775

[32]   D. Scrutinio and P. Giannuzzi, “Comorbidity in Patients Undergoing Coronary Artery Bypass Graft Surgery: Impact on Outcome and Implications for Cardiac Rehabilitation,” European Journal of Cardiovascular Prevention and Rehabilitation, Vol. 15, No. 4, 2008, pp. 379-385. http://dx.doi.org/10.1097/HJR.0b013e3282fd5c6f

[33]   J. Danesh, J. G. Wheeler, G. M. Hirschfield, S. Eda, G. Eiriksdottir, et al., “C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease,” The New England Journal of Medicine, Vol. 350, No. 14, 2004, pp. 1387-1397. http://dx.doi.org/10.1056/NEJMoa032804

[34]   S. E. Nissen, E. M. Tuzcu, P. Schoenhagen, T. Crowe, W. J. Sasiela, et al., “Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease,” The New England Journal of Medicine, Vol. 352, No. 1, 2005, pp. 29-38. http://dx.doi.org/10.1056/NEJMoa042000

[35]   D. M. Stafforini, “Biology of Platelet-Activating Factor Acetylhydrolase (PAF-AH, Lipoprotein Associated Phospholipase A2),” Cardiovascular Drugs and Therapy, Vol. 23, No. 1, 2009, pp. 73-83. http://dx.doi.org/10.1007/s10557-008-6133-8

[36]   A. Zalewski and C. Macphee, “Role of Lipoprotein-Associated Phospholipase A2 in Atherosclerosis: Biology, Epidemiology, and Possible Therapeutic Target,” Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 25, No. 5, 2005, pp. 923-931. http://dx.doi.org/10.1161/01.ATV.0000160551.21962.a7

[37]   C. J. Packard, D. S. O’Reilly, M. J. Caslake, A. D. McMahon, I. Ford, J. Cooney, C. H. Macphee, K. E. Suckling, M. Krishna, F. E. Wilkinson, A. Rumley and G. D. Lowe, “Lipoprotein-Associated Phospholipase A2 as an Independent Predictor of Coronary Heart Disease,” West of Scotland Coronary Prevention Study Group. New England Journal of Medicine, Vol. 343, No. 16, 2000, pp. 1148-1155. http://dx.doi.org/10.1056/NEJM200010193431603

[38]   E. S. Brilakis, J. P. McConnell, R. J. Lennon, A. A. Elesber, J. G. Meyer and P. B. Berger, “Association of lipoprotein-Associated Phospholipase A2 Levels with Coronary Artery Disease Risk Factors, Angiographic Coronary Artery Disease, and Major Adverse Events at Follow-Up,” European Heart Journal, Vol. 26, No. 2, 2005, pp. 137-144. http://dx.doi.org/10.1093/eurheartj/ehi010

[39]   C. Ballantyne, M. Cushman, B. Psaty, C. Furberg, K. T. Khaw, et al., “Collaborative Meta-Analysis of Individual Participant Data from Observational Studies of Lp-PLA2 and Cardiovascular Diseases,” European Journal of Preventive Cardiology, Vol. 14, No. 1, 2007, pp. 3-11. http://dx.doi.org/10.1097/01.hjr.0000239464.18509.f1

[40]   R. A. Pauwels, A. S. Buist, P. M. Calverley, C. R. Jenkins and S. S. Hurd, “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease,” NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. American Journal of Respiratory and Critical Care Medicine, Vol. 163, No. 5, 2001, pp. 1256-1276. http://dx.doi.org/10.1164/ajrccm.163.5.2101039

[41]   T. A. Seemungal, G. C. Donaldson, E. A. Paul, J. C. Bestall, D. J. Jeffries and J. A. Wedzicha, “Effect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary Disease,” Journal of Respiratory and Critical Care Medicine, Vol. 157, No. 5, 1998, pp. 1418-1422. http://dx.doi.org/10.1164/ajrccm.157.5.9709032

[42]   D. D. Sin and S. F. Man, “Why Are Patients with Chronic Obstructive Pulmonary Disease at Increased Risk of Cardiovascular Diseases? The Potential Role of Systemic Inflammation in Chronic Obstructive Pulmonary Disease,” Circulation, Vol. 107, No. 11, 2003, pp. 1514-1519. http://dx.doi.org/10.1161/01.CIR.0000056767.69054.B3

[43]   S. D. Sullivan, S. D. Ramsey and T. A. Lee, “The Eco- nomic Burden of COPD,” Chest, Vol. 117, No. 2, 2000, pp. 5S-9S. http://dx.doi.org/10.1378/chest.117.2_suppl.5S

[44]   A. Cohen, M. Katz, R. Katz, E. Hauptman and A. Schachner, “Chronic Obstructive Pulmonary Disease in Patients Undergoing Coronary Artery Bypass Grafting,” The Journal of Thoracic and Cardiovascular Surgery, Vol. 109, No. 3, 1995, pp. 574-581. http://dx.doi.org/10.1016/S0022-5223(95)70291-1

[45]   H. R. Anderson, C. Spix, S. Medina, J. P. Schouten, J. Castellsague, G. Rossi, D. Zmirou, G. Touloumi, B. Wojtyniak, A. Ponka, L. Bacharova, J. Schwartz and K. Katsouyanni, “Air Pollution and Daily Admissions for Chronic Obstructive Pulmonary Disease in 6 European Cities: Results from the APHEA Project,” European Respiratory Journal, Vol. 10, No. 5, 1997, pp. 1064-1071. http://dx.doi.org/10.1183/09031936.97.10051064

[46]   P. J. Barnes, “Mediators of Chronic Obstructive Pulmonary Disease,” Pharmacological Reviews, Vol. 56, No. 4, 2004, pp. 515-548. http://dx.doi.org/10.1124/pr.56.4.2

[47]   P. J. Barnes, “The Cytokine Network in Asthma and Chronic Obstructive Pulmonary Disease,” The Journal of Clinical Investigation, Vol. 118, No. 11, 2008, pp. 3546-3556. http://dx.doi.org/10.1172/JCI36130

[48]   A. G. Agusti, A. Noguera, J. Sauleda, E. Sala, J. Pons and X. Busquets, “Systemic Effects of Chronic Obstructive Pulmonary Disease,” European Respiratory Journal, Vol. 21, No. 2, 2003, pp. 347-360. http://dx.doi.org/10.1183/09031936.03.00405703

[49]   A. A. Eid, A. A. Ionescu, L. S. Nixon, V. Lewis-Jenkins, S. B. Matthews, T. L. Griffiths and D. J. Shale, “Inflammatory Response and Body Composition in Chronic Obstructive Pulmonary Disease,” American Journal of Respiratory and Critical Care Medicine, Vol. 164, No. 8, 2001, pp. 1414-1418. http://dx.doi.org/10.1164/ajrccm.164.8.2008109

[50]   M. Roland, A. Bhowmik, R. J. Sapsford, T. A. Seemungal, D. J. Jeffries, T. D. Warner and J. A. Wedzicha, “Sputum and Plasma Endothelin-1 Levels in Exacerbations of Chronic Obstructive Pulmonary Disease,” Thorax, Vol. 56, No. 1, 2001, pp. 30-35. http://dx.doi.org/10.1136/thorax.56.1.30

[51]   J. H. Vernooy, M. Kucukaycan, J. A. Jacobs, N. H. Chavanes, W. A. Buurman, M. A. Dentener and E. F. Wouters, “Local and Systemic Inflammation in Patients with Chronic Obstructive Pulmonary Disease: Soluble Tumor Necrosis Factor Receptors Are Increased in Sputum,” American Journal of Respiratory and Critical Care Medicine, Vol. 166, No. 9, 2002, pp. 1218-1224. http://dx.doi.org/10.1164/rccm.2202023

[52]   J. Danesh, R. Collins, P. Appleby and R. Peto, “Association of Fibrinogen, C-Reactive Protein, Albumin, or Leukocyte Count with Coronary Heart Disease: Meta-Analyses of Prospective Studies,” JAMA, Vol. 279, No. 18, 1998, pp. 1477-1482. http://dx.doi.org/10.1001/jama.279.18.1477

[53]   A. L. Hansell, J. A. Walk and J. B. Soriano, “What do Chronic Obstructive Pulmonary Disease Patients Die from? A Multiple Cause Coding Analysis,” European Respiratory Journal, Vol. 22, No. 5, 2003, pp. 809-814. http://dx.doi.org/10.1183/09031936.03.00031403

[54]   A. Bhowmik, T. A. Seemungal, R. J. Sapsford and J. A. Wedzicha, “Relation of Sputum Inflammatory Markers to Symptoms and Lung Function Changes in COPD Exacerbations,” Thorax, Vol. 55, No. 2, 2000, pp. 114-120. http://dx.doi.org/10.1136/thorax.55.2.114

[55]   T. A. Seemungal, G. C. Donaldson, A. Bhowmik, D. J. Jeffries and J. A. Wedzicha, “Time Course and Recovery of Exacerbations in Patients with Chronic Obstructive Pulmonary Disease,” American Journal of Respiratory and Critical Care Medicine, Vol. 161, No. 5, 2000, pp. 1608-1613. http://dx.doi.org/10.1164/ajrccm.161.5.9908022

[56]   S. L. Johnston, P. K. Pattemore, G. Sanderson, S. Smith, F. Lampe, et al., “Community Study of Role of Viral Infections in Exacerbations of Asthma in 9-11 Year Old Children,” British Medical Journal, Vol. 310, No. 6989, 1995, pp. 1225-1229. http://dx.doi.org/10.1136/bmj.310.6989.1225

[57]   G. Rohde, A. Wiethege, I. Borg, M. Kauth, T. T. Bauer, A. Gillissen, A. Bufe and G. Schultze-Werninghaus, “Respiratory Viruses in Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Hospitalisation: A Case-Control Study,” Thorax, Vol. 58, No. 1, 2003, pp. 37-42. http://dx.doi.org/10.1136/thorax.58.1.37

[58]   T. Seemungal, R. Harper-Owen, A. Bhowmik, I. Moric, G. Sanderson, S. Message, P. Maccallum, T.W. Meade, D. J. Jeffries, S. L. Johnston and J. A. Wedzicha, “Respiratory Viruses, Symptoms, and Inflammatory Markers in Acute Exacerbations and Stable Chronic Obstructive Pulmonary Disease,” American Journal of Respiratory and Critical Care Medicine, Vol. 164, No. 9, 2001, pp. 1618-1623. http://dx.doi.org/10.1164/ajrccm.164.9.2105011

[59]   H. E. Fleming, F. F. Little, D. Schnurr, P. C. Avila, H. Wong, J. Liu, S. Yagi and H. A. Boushey, “Rhinovirus-16 Colds in Healthy and in Asthmatic Subjects: Similar Changes in Upper and Lower Airways,” American Journal of Respiratory and Critical Care Medicine, Vol. 160, No. 1, 1999, pp. 100-108. http://dx.doi.org/10.1164/ajrccm.160.1.9808074

[60]   I. Tager and F. E. Speizer, “Role of Infection in Chronic Bronchitis,” New England Journal of Medicine, Vol. 292, No. 11, 1975, pp. 563-571.

[61]   D. W. Gump, C. A. Phillips, B. R. Forsyth, K. McIntosh, K. R. Lamborn and W. H. Stouch, “Role of Infection in Chronic Bronchitis,” The American Review of Respiratory Disease, Vol. 113, No. 4, 1976, pp. 465-474.

[62]   P. J. Barnes, K. F. Chung and C. P. Page, “Inflammatory Mediators of Asthma: An Update,” Pharmacological Reviews, Vol. 50, No. 4, 1998, pp. 515-596.

[63]   P. H. Howarth, K. S. Babu, H. S. Arshad, L. Lau, M. Buckley, W. McConnell, P. Beckett, M. Al Ali, A. Chauhan, S. J. Wilson, A. Reynolds, D. E. Davies and S. T. Holgate, “Tumour Necrosis Factor (TNFα) as a Novel Therapeutic Target in Symptomatic Corticosteroid Dependent Asthma,” Thorax, Vol. 60, No. 2, 2005, pp. 1012-1018. http://dx.doi.org/10.1136/thx.2005.045260

[64]   V. M. Keatings, P. D. Collins, D. M. Scott and P. J. Barnes, “Differences in Interleukin-8 and Tumor Necrosis Factor-alpha in Induced Sputum from Patients with Chronic Obstructive Pulmonary Disease or Asthma,” American Journal of Respiratory and Critical Care Medicine, Vol. 153, No. 2, 1996, pp. 530-534. http://dx.doi.org/10.1164/ajrccm.153.2.8564092

[65]   A. Mantovani, S. Sozzani, M. Locati, P. Allavena and A. Sica, “Macrophage Polarization: Tumor-Associated Macrophages as a Paradigm for Polarized M2 Mononuclear Phagocytes,” Trends in Immunology, Vol. 23, No. 11, 2002, pp. 549-555. http://dx.doi.org/10.1016/S1471-4906(02)02302-5

[66]   S. L. Johnston, A. Papi, P. J. Bates, J. G. Mastronarde, M. M. Monick and G. W. Hunninghake, “Low Grade Rhinovirus Infection Induces a Prolonged Release of IL-8 in Pulmonary Epithelium,” Journal of Immunology, Vol. 160, No. 12, 1998, pp. 6172-6181.

[67]   P. S. Thomas, “Tumour Necrosis Factor-α: The Role of this Multifunctional Cytokine in Asthma,” Immunology and Cell Biology, Vol. 79, No. 2, 2001, pp. 132-140. http://dx.doi.org/10.1046/j.1440-1711.2001.00980.x

[68]   J. Kidney, T. McManus and P. V. Coyle, “Exacerbations of Chronic Obstructive Pulmonary Disease,” Thorax, Vol. 57, No. 9, 2002, pp. 753-754. http://dx.doi.org/10.1136/thorax.57.9.753

[69]   K. J. Tracey and A. Cerami, “Tumor Necrosis Factor, Other Cytokines and Disease,” Annual Review of Cell Biology, Vol. 9, 1993, pp. 317-343. http://dx.doi.org/10.1146/annurev.cb.09.110193.001533

[70]   D. H. Broide, M. Lotz, A. J. Cuomo, D. A. Coburn, E. C. Federman and S. I. Wasserman, “Cytokines in Symptomatic Asthma Airways,” Journal of Allergy and Clinical Immunology, Vol. 89, No. 5, 1992, pp. 958-967. http://dx.doi.org/10.1016/0091-6749(92)90218-Q

[71]   A. R. Sousa, S. J. Lane, J. A. Nakhosteen, T. H. Lee and R. N. Poston, “Expression of Interleukin-1 Beta (IL-1Beta) and Interleukin-1 Receptor Antagonist (IL-1ra) on Asthmatic Bronchial Epithelium,” American Journal of Respiratory and Critical Care Medicine, Vol. 154, No. 4, 1996, pp. 1061-1066. http://dx.doi.org/10.1164/ajrccm.154.4.8887608

[72]   J. E. Gern, R. Vrtis, K. A. Grindle, C. Swenson, W. W. Busse, “Relationship of Upper and Lower Airway Cytokines to Outcome of Experimental Rhinovirus Infection,” American Journal of Respiratory and Critical Care Medicine, Vol. 162, No. 6, 2000, pp. 2226-2231. http://dx.doi.org/10.1164/ajrccm.162.6.2003019

[73]   M. M. Pizzichini, E. Pizzichini, A. Efthimiadis, A. J. Chauhan, S. L. Johnston, P. Hussack, J. Mahony, J. Dolovich and F. E. Hargreave, “Asthma and Natural Colds. Inflammatory Indices in Induced Sputum: A Feasibility Study,” American Journal of Respiratory and Critical Care Medicine, Vol. 158, No. 4, 1998, pp. 1178-1184. http://dx.doi.org/10.1164/ajrccm.158.4.9712082

[74]   S. D. Aaron, J. B. Angel, M. Lunau, K. Wright, C. Fex, N. le Saux and R. E. Dales, “Granulocyte Inflammatory Markers and Airway Infection During Acute Exacerbation of Chronic Obstructive Pulmonary Disease,” American Journal of Respiratory and Critical Care Medicine, Vol. 163, No. 2, 2001, pp. 349-355. http://dx.doi.org/10.1164/ajrccm.163.2.2003122

[75]   S. Gompertz, C. O’Brien, D. L. Bayley, S. L. Hill and R. A. Stockley, “Changes in Bronchial Inflammation During Acute Exacerbations of Chronic Bronchitis,” European Respiratory Journal, Vol. 17, No. 6, 2001, pp. 1112-1119. http://dx.doi.org/10.1183/09031936.01.99114901

[76]   S. A. Kharitonov and P. J. Barnes, “Exhaled Biomarkers,” Chest, Vol. 130, No. 5, 2006, pp. 1541-1546. http://dx.doi.org/10.1378/chest.130.5.1541

[77]   V. M. Keatings and P. J. Barnes, “Granulocyte Activation Markers in Induced Sputum: Comparison between Chronic Obstructive Pulmonary Disease, Asthma, and Normal Subjects,” American Journal of Respiratory and Critical Care Medicine, Vol. 155, No. 2, 1997, pp. 449-453. http://dx.doi.org/10.1164/ajrccm.155.2.9032177

[78]   E. J. Oudijk, J. W. Lammers and L. Koenderman, “Systemic Inflammation in Chronic Obstructive Pulmonary Disease,” European Respiratory Journal, Vol. 22, No. 46, 2003, pp. 5s-13s. http://dx.doi.org/10.1183/09031936.03.00004603a

[79]   A. Pesci, B. Balbi, M. Majori, G. Cacciani, S. Bertacco, P. Alciato and C. F. Donner, “Inflammatory Cells and Mediators in Bronchial Lavage of Patients with Chronic Obstructive Pulmonary Disease,” European Respiratory Journal, Vol. 12, No. 2, 1998, pp. 380-386. http://dx.doi.org/10.1183/09031936.98.12020380

[80]   G. Krommidas, K. Kostikas, G. Papatheodorou, A. Koutsokera, K. I. Gourgoulianis, C. Roussos, N. G. Koulouris and S. Loukides, “Plasma Leptin and Adiponectin in COPD Exacerbations: Associations with Inflammatory Biomarkers,” Respiratory Medicine, Vol. 104, No. 1, 2010, pp. 40-46. http://dx.doi.org/10.1016/j.rmed.2009.08.012

[81]   E. Sapey, D. Bayley, A. Ahmad, P. Newbold, N. Snell and R. A. Stockley, “Inter-Relationships between Inflammatory Markers in Patients with Stable COPD with Bronchitis: Intra-Patient and Inter-Patient Variability,” Thorax, Vol. 63, No. 6, 2008, pp. 493-499. http://dx.doi.org/10.1136/thx.2007.086751

[82]   M. Feldmann and S. R. Maini, “Role of Cytokines in Rheumatoid Arthritis: An Education in Pathophysiology and Therapeutics,” Immunological Reviews, Vol. 223, No. 1, 2008, pp. 7-19. http://dx.doi.org/10.1111/j.1600-065X.2008.00626.x

[83]   P. J. Barnes, “The Cytokine Network in Chronic Obstructive Pulmonary Disease,” American Journal of Respiratory Cell and Molecular Biology, Vol. 41, No. 6, 2009, pp. 631-638. http://dx.doi.org/10.1165/rcmb.2009-0220TR

[84]   S. N. Hoffman, J. A. TenBrook, M. P. Wolf, J. B. Wong, S. G. Pauker and D. N. Salem, “A Meta-Analysis of Randomized Controlled Trials Comparing Coronary Artery Bypass Graft with Percutaneous Transluminal Coronary Angioplasty: One-to Eight-Year Outcomes,” Journal of the American College of Cardiology, Vol. 41, No. 8, 2003, pp. 1293-1304. http://dx.doi.org/10.1016/S0735-1097(03)00157-8

[85]   J. C. Cleveland Jr., A. L. Shroyer, A. Y. Chen, E. Peterson and F. L. Grover, “Off-Pump Coronary Artery Bypass Grafting Decreases Risk-Adjusted Mortality and Morbidity,” The Annals of Thoracic Surgery, Vol. 72, No. 4, 2001, pp. 1282-1288. http://dx.doi.org/10.1016/S0003-4975(01)03006-5

[86]   I. Deblier, A. M. Sadowska, A. Janssens, I. Rodrigus and W. A. DeBacker, “Markers of Inflammation and Oxidative Stress in Patients Undergoing CABG with CPB with and without Ventilation of the Lungs: A Pilot Study,” Interactive CardioVasc Thoracic Surgery, Vol. 5, No. 4, 2006, pp. 387-391. http://dx.doi.org/10.1510/icvts.2006.128561

[87]   G. H. Almassi, T. Sommers, T. E. Moritz, A. L. Shroyer, M. J. London, G. K. Sethi, F. L. Grover and K. E. Hammermeister, “Stroke in Cardiac Surgical Patients: Determinants and Outcome,” The Annals of Thoracic Surgery, Vol. 68, No. 2, 1999, pp. 391-397. http://dx.doi.org/10.1016/S0003-4975(99)00537-8

[88]   K. M. Taylor, “Central Nervous System Effects of Cardiopulmonary Bypass,” The Annals of Thoracic Surgery, Vol. 66, No. 5, 1998, pp. S20-S24.

[89]   R. Ascione, C. T. Lloyd, M. J. Underwood, W. J. Gomes and G. D. Angelini, “On-Pump Versus Off-Pump Coronary Revascularization: Evaluation of Renal Function,” The Annals of Thoracic Surgery, Vol. 68, No. 2, 1999, pp. 493-498. http://dx.doi.org/10.1016/S0003-4975(99)00566-4

[90]   R. H. Jensen, M. Storgaard, R. Vedelsdal and N. Obel, “Impaired Neutrophil Chemotaxis after Cardiac Surgery,” Scandinavian Cardiovascular Journal, Vol. 29, No. 3, 1995, pp. 115-118. http://dx.doi.org/10.3109/14017439509107216

[91]   N. Kotani, H. Hashimoto, D. I. Sessler, M. Muraoka, J. S. Wang, M. F. O’Connor and A. Matsuki, “Neutrophil Number and Interleukin-8 and Elastase Concentrations in Bronchoalveolar Lavage Fluid Correlate with Decreased Arterial Oxygenation after Cardiopulmonary Bypass,” Anesthesia & Analgesia, Vol. 90, No. 5, 2000, pp. 1046- 1051. http://dx.doi.org/10.1097/00000539-200005000-00009

[92]   S. Tsuchida, D. Engelberts, V. Peltekova, N. Hopkins, H. Frndova, P. Babyn, C. McKerlie, M. Post, P. McLoughlin and B. P. Kavanagh, “Atelectasis Causes Alveolar Injury in Nonatelectatic Lung Regions,” American Journal of Respiratory and Critical Care Medicine, Vol. 174, No. 3, 2006, pp. 279-289. http://dx.doi.org/10.1164/rccm.200506-1006OC

[93]   L. L. Liu and M. A. Gropper, “Respiratory and Hemodynamic Management after Cardiac Surgery,” Current Treatment Options in Cardiovascular Medicine, Vol. 4, No. 2, 2002, pp. 161-169. http://dx.doi.org/10.1007/s11936-002-0036-y

[94]   F. L. Grover, K. E. Hammermeister and C. Burchfiel, “Initial Report of the Veterans Administration Preoperative Risk Assessment Study for Cardiac Surgery,” The Annals of Thoracic Surgery, Vol. 50, No. 1, 1990, pp. 12-26.

[95]   K. Kroenke, V. A. Lawrence, J. F. Theroux and M. R. Tuley, “Operative Risk in Patients with Severe Obstructive Pulmonary Disease,” JAMA, Vol. 152, No. 5, 1992, pp. 967-971. http://dx.doi.org/10.1001/archinte.1992.00400170057011